Ex ante evaluation of risk adjustment models for prospective provider payment: a conceptual framework and empirical application [0.03%]
基于提供者预付的视角评估风险调节模型的概念框架及实证分析
Andreea Panturu,Richard van Kleef,Frank Eijkenaar
Andreea Panturu
Alternative payment models (APMs) aim to improve efficiency and fairness in healthcare by shifting financial responsibility from payers to providers. Given their prospective nature, APMs require effective risk adjustment (RA) to prevent ris...
Demographic and health impacts of women's bodily autonomy: switching prescription requirements for emergency contraceptives [0.03%]
关于女性身体自主权的 demographic 和健康影响：改变紧急避孕药的处方要求
Fabian Grünwald,Tom Stargardt
Fabian Grünwald
Over the past decades, most European countries switched emergency contraceptive availability from prescription to over-the-counter (OTC) status. However, the effect of OTC switches on emergency and regular contraceptive use, on demographic ...
Estimating the magnitude and scope of disability-related direct costs: a systematised review [0.03%]
估算与残疾相关的直接费用的规模和范围：系统评价
Lena Morgon Banks,Zachary Morris,Sara Rotenberg et al.
Lena Morgon Banks et al.
The cost-effectiveness of enzyme replacement therapies versus best supportive care for treating late onset Pompe disease in the UK NHS [0.03%]
英国NHS中酶替代疗法治疗庞贝病的疗效成本分析研究
Matthew Walton,Nyanar Jasmine Deng,Mark Corbett et al.
Matthew Walton et al.
Objective: To assess the cost-effectiveness of enzyme replacement therapy (ERT) compared with best supportive care (BSC) for late-onset Pompe disease (LOPD) in a UK NHS setting. ...
Multinational stakeholder engagement to inform future development and refinement of the EuroQol toddler and infant populations (EQ-TIPS) [0.03%]
利益攸关方的跨国参与 以便为EuroQol幼儿和婴儿人群(EQ-TIPS)的未来开发和改进提供信息
J Verstraete,S Schieskow,J Jelsma et al.
J Verstraete et al.
Background: The EQ-TIPS (v2.0) is an experimental instrument to measure and value the HRQoL in children aged 0-3 years. This study consulted experts and caregivers to (a) review the instrument's wording and content for gl...
Cost analysis of transthyretin amyloid cardiomyopathy in heart failure patients with preserved ejection fraction in Spain [0.03%]
西班牙心力衰竭患者（射血分数保留）中转甲状腺素蛋白淀粉样心脏病理成本分析
Pablo García-Pavía,José Manuel García-Pinilla,Javier Rejas-Gutierrez et al.
Pablo García-Pavía et al.
Background: Transthyretin amyloid cardiomyopathy (ATTR-CA) is a progressive, fatal disease that often presents as heart failure with preserved ejection fraction (HFpEF). To date, scarce evidence about the economic burden ...
Economic burden of eosinophilic esophagitis in the first year after diagnosis in Spain: A direct medical cost analysis [0.03%]
西班牙对 eosinophilic esophagitis 的经济负担：诊断后第一年的直接医疗费用分析
Leticia Rodriguez-Alcolado,Isaac Aranda-Reneo,Sergio Casabona et al.
Leticia Rodriguez-Alcolado et al.
Background: Despite its increasing prevalence, the economic impact of eosinophilic esophagitis (EoE) in Europe is understudied and direct economic costs remain unknown. ...
Eliciting discounting model and direction at the individual level with time trade-off follow-up questions [0.03%]
使用时间交换抉择的后续问题在个人层面上进行折现模型和方向的挖掘
Michał Jakubczyk
Michał Jakubczyk
Objective: Time preference is increasingly considered in health state valuation. As its inclusion impacts the produced value sets, it is important to account for it using the correct specification. Various discounting fun...
Is next generation sequencing for the diagnosis of rare diseases worth its cost? A user-based approach to valuation [0.03%]
下一代测序技术在罕见病诊断中的应用是否物有所值？基于用户的估值方法
Karen V MacDonald,Sebastian Heidenreich,Nicolas Krucien et al.
Karen V MacDonald et al.
Background: Next generation sequencing (NGS) can decrease the diagnostic odyssey for patients with rare diseases. However, valuing the combination of health and non-health outcomes associated with NGS is challenging. Whil...
Long-term effectiveness and cost-effectiveness of testing for alemtuzumab antidrug antibodies to guide treatment in multiple sclerosis: a modelling study [0.03%]
奥雷路单抗抗药物抗体检测的长期有效性和成本效益：基于模型的研究
Timothy Jamieson,Florian Tomini,Sharmilee Gnanapavan et al.
Timothy Jamieson et al.
Biologic therapies are increasingly used in multiple sclerosis (MS), but often provoke anti-drug antibodies, potentially leading to treatment failure. Testing for anti-drug antibodies to guide treatment switching could improve clinical- and...